Overview

Hepatic Impairment, Cholestatic Liver Disease, & NASH With Advanced Fibrosis & Normal Hepatic Function

Status:
Recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

This will be a Phase 1, Open-label Study of Participants with Hepatic Impairment, Cholestatic Liver Disease, and NASH with Advanced Fibrosis and Normal Hepatic Function

Phase:

Phase 1

Details

Lead Sponsor:

Zydus Discovery DMCC
Zydus Therapeutics Inc.